New hope for hard-to-treat lymphoma: targeted therapy plus chemo shows promise
NCT ID NCT05600686
First seen Dec 08, 2025 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tests a two-step treatment for people with a fast-growing type of lymphoma that hasn't been treated yet. First, a targeted drug (loncastuximab tesirine) plus rituximab is given, followed by a standard chemotherapy cocktail (DA-EPOCH-R). The goal is to see if this approach leads to more complete remissions. About 24 adults with high-risk features will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOUBLE-EXPRESSOR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UC San Diego Moores Cancer Center
RECRUITINGSan Diego, California, 92037, United States
Contact Email: •••••@•••••
Contact
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.